Cushing's Syndrome clinical trials at UC Irvine

1 in progress, 0 open to eligible people

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
Sorry, not currently recruiting here
This will be a randomized, double-blind study to evaluate the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor.
Orange, California and other locations

Our lead scientists for Cushing's Syndrome research studies include Qin Yang, MD.

Last updated: January 26, 2023

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor